MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2023-24)
- Udyam number
- UDYAM-BR-26-0020662
RBS Drug Formulation Private Limited
RBS Drug Formulation Private Limited - business services in Patna, Bihar, India. FY 2026 financials & compliance.
Revenue · FY 2024
₹30.88 Lakh
▲ 2% YoY
Net profit · FY 2024
₹3,293
Net margin 0.1%
EBITDA · FY 2024
₹4,449
EBITDA margin 0.1%
Authorised capital
₹5 Lakh
Registered with MCA
Paid-up capital
₹5 Lakh
Issued & subscribed
Company age
9 yrs
Est. 2017
Directors on board
3
As per MCA filings
Active GSTINs
1
GST registered
About RBS Drug Formulation Private Limited
Data last updated:
RBS Drug Formulation Private Limited is a private limited company based in Patna, Bihar, India. It operates in the service-based operations segment of the business services sector. It was incorporated on 06 June 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Patna, under CIN U74999BR2017PTC034794. Its GSTIN is 10AAICR3418E1ZW (Bihar).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors including Rita Sharma and Ravi Raushan Kumar.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at H/O Of Satyendra Sharma Road No. – 6B Rajendra Nagar, Patna, Bihar, India – 800016.
As per the financials filed for FY 2024, the company reported a revenue of ₹30.88 Lakh, a growth of 2% compared to the previous year. For the same year it recorded a net profit of ₹3,293 (net margin 0.1%) and EBITDA of ₹4,449 (EBITDA margin 0.1%). Revenue has grown at a compounded annual rate (CAGR) of 70% over three years and 46% over five years.
RBS Drug Formulation Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-BR-26-0020662). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
CIN U74999BR2017PTC034794
Registration Number 034794
Incorporation Date 06 June 2017
ROC Patna
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-BR-26-0020662
Recognitions & Rankings of RBS Drug Formulation
Contact details
RBS Drug Formulation Private Limited's registered office is in Patna, Bihar. Its e-mail address is in the company report.
- Email
- Registered AddressH/O Of Satyendra Sharma Road No. – 6B Rajendra Nagar, Patna, Bihar, India – 800016
- IndustryBusiness Services, Other Services, Miscellaneous Business Activities
To see the full contact details of RBS Drug Formulation Private Limited, buy the company report.
Comprehensive company report
RBS Drug Formulation Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of RBS Drug Formulation is trade. In detail, this covers retail trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading |
To see the full business activity and turnover split of RBS Drug Formulation Private Limited, buy the company report.
Financials of RBS Drug Formulation Private Limited
FY 2025 filings availableRBS Drug Formulation Private Limited reported revenue of ₹30.88 Lakh (up 2% YoY) for FY 2024.
Revenue · FY 2024
₹30.88 Lakh ▲ 2%
Net profit · FY 2024
₹3,293 margin 0.1%
EBITDA · FY 2024
₹4,449 margin 0.1%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 2%
3 years · compounded
▲ 70%
5 years · compounded
▲ 46%
EBITDA CAGR growth
1 year
▼ 59%
3 years · compounded
▲ 20%
5 years · compounded
▲ 76%
Revenue has grown at a compounded annual rate (CAGR) of 46% over five years, including 2% growth in the latest year. EBITDA fell 59% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹4,449 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹3,293 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 0.1% | ||||
| Net Profit Margin | 0.1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of RBS Drug Formulation Private Limited, buy the company report.
Board of directors of RBS Drug Formulation Private Limited
RBS Drug Formulation has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rita Sharma Also directs: Advanced Ent Centre Private Limited | Director | 06 Jun 2017 | 9 Years 5 Months | Current |
| Ravi Raushan Kumar | Director | 23 Mar 2021 | 5 Years 7 Months | Current |
| Saumya Sharma Also directs: Advanced Ent Centre Private Limited | Director | 29 May 2024 | 2 Years 5 Months | Current |
Peer comparison
RBS Drug Formulation Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (retail trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Zoid Labs (India) Private Limited | ₹30.9 Lakh (FY 2024) | -42.0% | Ernakulam, Kerala, India | |||
| Maxinique Solution Private Limited | ₹30.9 Lakh (FY 2025) | -89.0% | Jhajjar, Haryana, India | |||
| K R Govindaraju Constructions Private Limited | ₹30.9 Lakh (FY 2024) | -63.0% | Mysore, Karnataka, India | |||
| Sparnita Paints Private Limited | ₹30.9 Lakh (FY 2021) | Lucknow, Uttar Pradesh, India | ||||
| R Ar Micro Equipments Private Limited | ₹30.89 Lakh (FY 2024) | 13.0% | Coimbatore, Tamil Nadu, India | |||
| RBS Drug Formulation Private Limitedthis company | ₹30.88 Lakh (FY 2024) | ₹3,293 | 0.1% | 2.0% | Patna, Bihar, India | |
| Kivtas Technologies Private Limited | ₹30.88 Lakh (FY 2023) | 89.0% | Hyderabad, Telangana, India | |||
| Enva Plax Holdings Private Limited | ₹30.87 Lakh (FY 2024) | -43.0% | Gurgaon, Haryana, India | |||
| Dio Apparel Private Limited | ₹30.86 Lakh (FY 2025) | 1606.0% | Kolkata, West Bengal, India | |||
| Patahi Farmer Producer Company Limited | ₹30.86 Lakh (FY 2022) | 162.0% | East Champaran, Bihar, India | |||
| Twinzkart Private Limited | ₹30.85 Lakh (FY 2025) | 9.0% | Delhi, India |
To see the full peer comparison of RBS Drug Formulation Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving RBS Drug Formulation Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for RBS Drug Formulation Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
RBS Drug Formulation has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 10AAICR3418E1ZW | Bihar | Active | 04 Sep 2017 |
To see the full GST registrations and return filing status of RBS Drug Formulation Private Limited, buy the company report.
Recent activity
RBS Drug Formulation Private Limited has 6 board changes on record since 2017: 3 appointments and 3 cessations. The latest: Ajay Kumar ceased to be Director on 29 May 2024.
AGM
Rbs Drug Formulation Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Rbs Drug Formulation Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Patna.
Ceased
Ajay Kumar ceased to be Director.
Appointed
Saumya Sharma was appointed as Director.
Ceased
Rakesh Nayan ceased to be Director.
Appointed
Ravi Raushan Kumar was appointed as Director.
Ceased
Saroj Kumar ceased to be Director.
Appointed
Rita Sharma was appointed as Director.
Incorporation
06 Jun 2017
Rbs Drug Formulation Private Limited was registered on 06 Jun 2017 with Roc Patna & aged 9 years 5 months as per MCA records.
Frequently asked questions
RBS Drug Formulation is an active private limited company based in Patna, Bihar, India. The company works in other services, within the business services industry. It was incorporated on 06 June 2017 (9+ years old) and is registered under CIN U74999BR2017PTC034794.
RBS Drug Formulation has 3 current directors:
- Rita Sharma - Director
- Ravi Raushan Kumar - Director
- Saumya Sharma - Director
The latest financial statements of RBS Drug Formulation on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.
The GSTIN of RBS Drug Formulation is 10AAICR3418E1ZW, registered in Bihar.
The CIN (Corporate Identification Number) of RBS Drug Formulation is U74999BR2017PTC034794. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
RBS Drug Formulation was incorporated on 06 June 2017, making it 9+ years old. It is registered with the Registrar of Companies, Patna.
The peers of RBS Drug Formulation by revenue are Zoid Labs (India) Private Limited, Maxinique Solution Private Limited, K R Govindaraju Constructions Private Limited, Sparnita Paints Private Limited, R Ar Micro Equipments Private Limited and 5 more, all in the same principal business activity (retail trading).
Ajay Kumar ceased to be Director on 29 May 2024. Saumya Sharma was appointed as Director on 29 May 2024. Rakesh Nayan ceased to be Director on 24 Mar 2021. RBS Drug Formulation has 6 board changes on record in total.
Yes, RBS Drug Formulation is registered as a micro enterprise under Udyam registration (number: UDYAM-BR-26-0020662).
The registered office of RBS Drug Formulation is at HO Of Satyendra Sharma Road No. – 6B Rajendra Nagar, Patna, Bihar, India – 800016.
RBS Drug Formulation operates in the business services industry, in the other services segment.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages